Oppenheimer resumed coverage on Dyne Therapeutics with a new price target
$DYN
Biotechnology: Pharmaceutical Preparations
Health Care
Oppenheimer resumed coverage of Dyne Therapeutics with a rating of Outperform and set a new price target of $34.00
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
6/24/2025 | $13.00 | Mkt Perform | Bernstein |
6/11/2025 | $37.00 | Outperform | Raymond James |
6/2/2025 | $34.00 | Outperform | Oppenheimer |
5/29/2025 | $46.00 | Outperform | Evercore ISI |
3/12/2025 | $50.00 | Outperform | BMO Capital Markets |
3/7/2025 | $50.00 | Sector Outperform | Scotiabank |
12/13/2024 | $46.00 | Outperform | Robert W. Baird |
11/26/2024 | $45.00 | Outperform | RBC Capital Mkts |